Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure-Reference-Cited by-同舟云学术

Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure

Published:2020-01 Issue: Volume:866 Page:172810
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Nambu Hideo,Takada Shingo,Fukushima Arata,Matsumoto Junichi,Kakutani Naoya,Maekawa Satoshi,Shirakawa Ryosuke,Nakano Ippei,Furihata Takaaki,Katayama Takashi,Yamanashi Katsuma,Obata Yoshikuni,Saito Akimichi,Yokota Takashi,Kinugawa Shintaro

Funder

Scientific Research

Challenging Exploratory Research

Japan Foundation for Applied Enzymology

Hokkaido Heart Association

MSD Life Science Foundation

Uehara Memorial Foundation

Cardiovascular Research Fund, Tokyo, Japan

Fukuda Memorial Foundation for Medical Research

Kimura Memorial Heart Foundation Research

SENSHIN Medical Research Foundation

Nakatomi Foundation

Japan Heart Foundation

Japan Science Society

Japan Science and Technology Agency

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Pharmacology

Reference49 articles.

1. Pharmacologic and surgical interventions to improve functional capacity in heart failure;Abbate;Heart Fail. Clin.,2015

2. The failing heart relies on ketone bodies as a fuel;Aubert;Circulation,2016

3. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure;Byrne;JACC Basic Transl. Med.,2017

4. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice;Camporez;Proc. Natl. Acad. Sci. U.S.A.,2016

5. Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics;Carbone;Diabetes Obes. Metab.,2018

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure;JAMA Network Open;2024-04-04

2. Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction;European Journal of Heart Failure;2024-03-11

3. Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction;The American Journal of Medicine;2024-02

4. The Effect of Empagliflozin on Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway in Patients with Type 2 Cardiorenal Syndrome;The Anatolian Journal of Cardiology;2024

5. The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy;Frontiers in Cardiovascular Medicine;2023-12-06